Sanofi to Acquire Translate Bio in $3.2 Billion Deal

Paul, Weiss is representing Translate Bio in its approximately $3.2 billion all-cash sale to global biopharmaceutical company Sanofi. Massachusetts-based Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity.

Under the terms of the transaction, Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share via a tender offer. The transaction is expected to close in the third quarter of 2021, subject to customary closing conditions and regulatory approvals.

The Paul, Weiss team includes corporate partners Krishna Veeraraghavan and John Kennedy, and counsel Oliver Board; intellectual property partner Jonathan Ashtor; tax partner Robert Holo; executive compensation partners Jean McLoughlin and Lawrence Witdorchic and counsel Nicole Tark; litigation partner Charles Rule and counsel Daniel Howley; antitrust counsel Marta Kelly; and international trade counsel Richard Elliott.

Share this